EGFR exon 2-7 deletion + EGFR amplification
|
NSCLC
|
EGFR exon 2-7 deletion + EGFR amplification
|
NSCLC
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR exon 2-7 deletion + EGFR amplification
|
GBM
|
EGFR exon 2-7 deletion + EGFR amplification
|
GBM
|
bevacizumab + osimertinib Sensitive: C3 – Early Trials
|
bevacizumab + osimertinib Sensitive: C3 – Early Trials
|